Jay M. Lee, M.D., is the Surgical Director of the Thoracic Oncology Program, and Associate Professor of Surgery (Tenure Track) at the David Geffen School of Medicine at UCLA.
He received his medical degree from UCLA and training in General Surgery at Georgetown and Duke University Medical Centers. He completed a Thoracic Research Fellowship at Memorial Sloan Kettering Cancer Center and received Thoracic Surgery training at the Brigham and Women’s Hospital and Children’s Hospital Boston at Harvard Medical School.
Dr. Lee is on the Steering Committee of several neoadjuvant or perioperative immunotherapy or targeted therapy trials in resectable non-small cell lung cancer (NSCLC) including LCMC3 (atezolizumab), CANOPY-N (canakinumab and/or pembrolizumab), NAUTIKA1 (alectinib, entrectinib, vemurafenib plus cobimetinib, pralsetinib, or stereotactic body radiation therapy plus atezolizumab), GEOMETRY-N (capmatinib), and HORIZON-2 (alectinib; divarasib). Dr. Lee is also the Study Co-Chair for the Skyscraper-15 (phase 3 trial of adjuvant atezolizumab and tiragolumab). He is on the Scientific Advisory Committee for several Phase 3 Merck trials: TroFuse-019 (peri-adjuvant MK2870, TROP2-ADC), Peri-adjuvant V940-009 (individualized neoantigen mRNA vaccine), and INTerpath-002 (adjuvant V940) with pembrolizumab. Dr. Lee is on the Executive Committee of the LCMC4/LEADER trial to define driver mutations in early stage NSCLC. Dr. Lee is an author on numerous clinical trials including LCMC3 and IMPower 010 (adjuvant atezolizumab). Dr. Lee has published extensively in the field of thoracic oncology and has a funded research laboratory.